Výsledky vyhledávání - "Mary Kay Schultz"

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

Autor: S. Gail Eckhardt, Michele Basche, Laura Q M Chow, Cindy L. O'Bryant, S. Grolnic, Lia Gore, Mark Morrow, Mary Kay Schultz

Publikováno v: Cancer Chemotherapy and Pharmacology. 62:631-646

This phase I study was conducted to evaluate the safety, tolerability, pharmacological properties and biological activity of the combination of the lonafarnib, a farnesylproteintransferase (FTPase) inhibitor, with gemcitabine and cisplatin in patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7ce6d37b0ff81b1ef6152ae6471263c
https://doi.org/10.1007/s00280-007-0646-x

Zobrazit plný text záznamu

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

Autor: Michele Basche, Michael Kangas, Kaye L. Roberts, R. S. Addison, Brian R. Creese, Mark Morrow, S. Gail Eckhardt, Lia Gore, Cindy L. O'Bryant, Samir E. Witta, Daniel L. Gustafson, Scott N. Holden, Mary Kay Schultz, Kat Davis, Jane C. Moore, Thu Suong T. Nguyen, Adrah Levin

Publikováno v: Clinical Cancer Research. 12:5471-5480

Purpose: PI-88 is a mixture of highly sulfated oligosaccharides that inhibits heparanase, an extracellular matrix endoglycosidase, and the binding of angiogenic growth factors to heparan sulfate. This agent showed potent inhibition of placental blood

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209fdf9b46efd2811b12729be5fbe5be
https://doi.org/10.1158/1078-0432.ccr-05-2423

Zobrazit plný text záznamu

Staffing the Operating Room

Autor: Mary Kay Schultz, Cheryl C. Barratt

Publikováno v: The Journal of Nursing Administration. 27:27-31

Staffing the operating room requires a different approach than staffing inpatient units. Of course, there are similarities, namely: assuring safe, cost-effective care; dealing with fluctuating workloads; using various types of caregivers; and maximiz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a5fd7250f246e584125b119f9bdf0f
https://doi.org/10.1097/00005110-199712000-00009

Zobrazit plný text záznamu

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

Autor: Cindy L. O'Bryant, Astrid Schott, Candice McCoy, Catherine Scholz, Mace L. Rothenberg, Alan B. Sandler, Lia Gore, Denise Coffin, Mary Kay Schultz, S. Gail Eckhardt

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 14(14)

Purpose: To evaluate the toxicity profile, pharmacologic, and biological properties of 3-pyridylmethyl N-{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate (MS-275), a histone deacetylase inhibitor, when administered orally on three different dosing sched

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf4f685f34004c30ea68be2202c7ccef
https://pubmed.ncbi.nlm.nih.gov/18579665

Zobrazit plný text záznamu

92 A phase I, pharmacological and biological study of Sarasar® (Ionafarnib, SCH 66336), cisplatin and gemcitabine in patients with advanced solid tumors

Autor: S. Grolnic, Mark Morrow, S. G. Eckhardt, Lia Gore, Scott N. Holden, Cindy L. O'Bryant, Michele Basche, Mary Kay Schultz

Publikováno v: European Journal of Cancer Supplements. 2:30-31

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ffe5336981ab9fd2b6894f84ed3a7342
https://doi.org/10.1016/s1359-6349(04)80100-9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání